title: [Diagnosis and treatment of pneumocystis jirovecii pneumonia].
authors.affiliation: Klinik für Gastroenterologie, Hepatologie und Infektiologie, Ortenauklinik Offenburg-Gengenbach.
authors.forename: J P
authors.initials: JP
authors.lastname: Borde
authors.forename: W B
authors.initials: WB
authors.lastname: Offensperger
authors.forename: K
authors.initials: K
authors.lastname: de With
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use; D053626:Atovaquone / Q000009:adverse effects / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D000077336:Caspofungin; D003937:Diagnosis, Differential; D054714:Echinocandins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D055666:Lipopeptides; D008168:Lung / Q000473:pathology; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D010419:Pentamidine / Q000009:adverse effects / Q000627:therapeutic use; D045363:Pneumocystis carinii; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D014057:Tomography, X-Ray Computed; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use; D016597:Trimetrexate / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000077336:Caspofungin; D016597:Trimetrexate; D053626:Atovaquone